Comparative Pharmacology
Head-to-head clinical analysis: KIRSTY versus MICRONOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KIRSTY versus MICRONOR.
KIRSTY vs MICRONOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the central nervous system, potentiating serotonergic activity.
Progestin-only contraceptive; suppresses ovulation by inhibiting gonadotropin release, thickens cervical mucus, and alters endometrial lining to prevent implantation.
Not established; no approved dosing available.
0.35 mg orally once daily, taken at the same time each day.
None Documented
None Documented
12.4 ± 3.1 hours in healthy adults; prolonged in hepatic impairment (24–36 hours) and in elderly (15–20 hours).
Terminal elimination half-life is approximately 5-14 hours (mean 7.6-8.7 hours). In clinical context, the short half-life requires daily dosing for contraceptive efficacy.
Primarily hepatic metabolism to inactive metabolites; 5% excreted renally unchanged; 95% eliminated in feces via biliary secretion.
Approximately 50-80% of a dose is excreted in urine as glucuronide and sulfate conjugates of norethindrone and its metabolites; about 20-40% is excreted in feces via biliary elimination.
Category C
Category C
Progestin-Only Contraceptive
Progestin-Only Contraceptive